13 results on '"M. Phillips-Houlbracq"'
Search Results
2. Atélectasies lobaires multiples secondaires à des sténoses bronchiques : un phénotype d’asthme sévère à éosinophiles ?
- Author
-
M. Phillips-Houlbracq, M.P. Debray, A. Guyard, R. Khoury, M.C. Dombret, M. Le Brun, L. Deneuville, C. Dupin, and C. Taillé
- Subjects
Pulmonary and Respiratory Medicine - Published
- 2023
- Full Text
- View/download PDF
3. L’inflammation de type 2 : au-delà des bronches ?
- Author
-
A. Magnan, M. Phillips-Houlbracq, P. Chanez, and A.T. Dinh Xuan
- Subjects
Pulmonary and Respiratory Medicine ,business.industry ,Medicine ,business - Published
- 2021
- Full Text
- View/download PDF
4. Exploration de nouvelles approches de prise en charge des patients asthmatiques
- Author
-
L. Guilleminault, P. Devillier, L. Giovannini-Chami, and M. Phillips-Houlbracq
- Subjects
Pulmonary and Respiratory Medicine ,business.industry ,Medicine ,business - Published
- 2021
- Full Text
- View/download PDF
5. Biothérapies dans l’asthme sévère : desétudescliniques àlapratique
- Author
-
M. Phillips-Houlbracq, C. Dupin, G. Devouassoux, and L. Portel
- Subjects
Pulmonary and Respiratory Medicine ,business.industry ,Medicine ,business - Published
- 2021
- Full Text
- View/download PDF
6. Évolution après transplantation pulmonaire pour fibrose chez les patients porteurs d’une mutation du complexe télomérase
- Author
-
G. Prévot, A. Roux, Romain Lazor, Hervé Mal, Sylvain Marchand-Adam, J. Le Pavec, Raphael Borie, Caroline Kannengiesser, Jean-Marc Naccache, Johanna Claustre, Sandrine Hirschi, Vincent Cottin, Antoine Froidure, Martine Reynaud-Gaubert, Stéphane Jouneau, M. Phillips Houlbracq, Lidwine Wemeau-Stervinou, S. Park, Bruno Crestani, and Hilario Nunes
- Subjects
Pulmonary and Respiratory Medicine - Abstract
Introduction Les patients atteints d’une pneumopathie interstitielle diffuse associee a une mutation d’un gene regulateur du complexe telomerase (TRG) semblent presenter une moins bonne survie et des complications hematologiques plus frequentes apres transplantation pulmonaire (TxP). L’objectif de cette etude etait de determiner l’evolution apres TxP de ces patients dans une cohorte francaise. Methodes Tous les patients porteurs d’une mutation d’un TRG ayant eu une TxP en France entre 2009 et 2017 ont ete identifies par les centres de transplantation et le reseau francais OrphaLung. Resultats Vingt-sept patients ont ete inclus, dont 67 % etaient des hommes, avec des mutations de TERT (n = 17), TERC (n = 6), et RTEL1 (n = 4). Avant la greffe, 19 (70 %) presentaient une atteinte hematologique, dont 6 un syndrome myelodysplasique et 14 une hepatopathie. L’âge median lors de la TxP etait de 54 (± 9) ans. Apres la TxP, tous les patients presentaient une anemie, 74 % une thrombopenie, et 54 % une neutropenie. Quatre patients ont presente des complications hepatiques severes : une hemochromatose post transfusionnelle, une fibrose hepatique et deux patients une hypertension portale. 26 % ont presente une dysfonction chronique du greffon dans un delai median de 2,1 (± 1,3) ans. Quinze receveurs sont decedes (56 %) au cours du suivi. La mediane de survie apres la TP etait de 4,4 ans. La presence d’une myelodysplasie avant la TxP etait associee a une diminution de la survie (p Conclusion La survie apres TxP des patients porteurs d’une mutation d’un TRG est comparable a celle des patients sans mutation. Une TxP est possible apres un bilan exhaustif des comorbidites extra-respiratoires et une prise en charge post-greffe adaptee. La presence d’un syndrome myelodysplasique avant la greffe doit faire rediscuter le projet de greffe.
- Published
- 2019
- Full Text
- View/download PDF
7. Détection des variants de fusion du gène ALK par séquençage massif parallèle ciblé à partir d’ARN et réponse au crizotinib dans les cancers pulmonaires non à petites cellules
- Author
-
M. Giaj Levra, Julien Fauré, Julie Mondet, Elizabeth Brambilla, M. Phillips Houlbracq, Michael Duruisseaux, F. De Fraipont, D. Moro-Sibilot, Gilbert Ferretti, Sylvie Lantuejoul, Pierre Hainaut, J. Pinsolle, Amandine Chatagnon, Anne-Claire Toffart, Nelly Magnat, and A. Mcleer
- Subjects
Pulmonary and Respiratory Medicine ,Crizotinib ,medicine ,Biology ,Molecular biology ,medicine.drug - Abstract
Introduction Differents variants de fusion ont ete decrits dans les rearrangements du gene ALK au sein des cancers pulmonaires non a petites cellules (CPNPC) et influeraient sur la sensibilite cellulaire au traitement par crizotinib. Le but de cette etude etait de tester et d’ameliorer l’efficacite du sequencage massif parallele (NGS) a partir d’ARN base sur des PCR multiplexes (RNA-seq) dans la detection du rearrangement et des variants de fusion ALK par rapport a l’immunohistochimie (IHC) et l’hybridation in situ en fluorescence (FISH) dans des echantillons de CPNPC. Le second objectif etait de mettre en evidence un lien entre la nature du variant de fusion ALK et la reponse au crizotinib. Methodes Cinquante-trois echantillons fixes au formol et inclus en paraffine ALK-positifs en FISH et/ou en IHC et 23 echantillons ALK-negatifs ont ete testes par RNA-seq. Dans un 2e temps, un protocole associant le RNA-seq a une PCR ancree multiplexe a ete evalue sur 10 echantillons en echec apres RNA-seq. Resultats Un resultat concluant par RNA-seq a ete obtenu dans 75 % des echantillons. Parmi les 33 cas ALK-positifs en RNA-seq, un transcrit de fusion a ete identifie parmi 27 echantillons. Comparees a l’association IHC/FISH, la sensibilite et la specificite du RNA-seq etaient respectivement de 80 et 100 %. Dans les cas ALK-positifs en IHC et en FISH, le RNA-seq a detecte un rearrangement ALK dans 100 % des cas analysables. Le RNA-seq a rendu un resultat concluant dans tous les cas equivoques et/ou borderlines en FISH et IHC. Concernant les cas discordants en IHC et FISH, le RNA-seq a ete mis en echec pour 5 des 7 echantillons. Sur les 10 echantillons consideres en echec apres RNA-seq testes, l’ajout d’une PCR ancree multiplexe dans le protocole de RNA-seq a permis de detecter 3 transcrits de fusion dont un variant CLIP1(12)-ALK(20) jamais decrit auparavant. Au sein des patients traites par crizotinib, la survie sans progression mediane etait plus allongee pour ceux presentant un variant 1 ou 2 d’EML4-ALK par rapport a ceux arborant un variant 3a/b (314 contre 192 jours, respectivement ; p = 0,1743). Conclusion Le RNA-seq est efficace pour le diagnostic des rearrangements ALK dans les CPNPC et pourrait etre integre a l’algorithme diagnostique de cette anomalie. De plus, il autorise l’identification des transcrits de fusion ALK qui pourraient constituer un marqueur pronostique chez ces patients.
- Published
- 2018
- Full Text
- View/download PDF
8. FRI0299 Pulmonary Arterial Hypertension in Idiopathic Inflammatory Myopathies: Data from The French Pulmonary Hypertension Registry and Review of The Literature
- Author
-
Sébastien Sanges, Vincent Cottin, Cécile Yelnik, Kuberaka Mariampillai, E. Hachulla, M. Phillips-Houlbracq, Olivier Benveniste, Marc Lambert, P.Y. Hatron, Laurence Rottat, Luc Mouthon, Olivier Sitbon, Marc Humbert, D. Launay, Christophe Pison, J. Inamo, and Christophe Deligny
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Immunology ,Microangiopathy ,Interstitial lung disease ,Overlap syndrome ,Dermatomyositis ,medicine.disease ,Pulmonary hypertension ,General Biochemistry, Genetics and Molecular Biology ,Surgery ,Idiopathic inflammatory myopathies ,Rheumatology ,Internal medicine ,Cohort ,Biopsy ,medicine ,Immunology and Allergy ,business - Abstract
Background Occurrence of pulmonary arterial hypertension (PAH) in idiopathic inflammatory myopathies (IIM) without extensive interstitial lung disease (ILD) has been rarely described. Objectives This study aimed to report all cases with association of PAH and IIM in the French Pulmonary Hypertension (PH) Registry, to identify IIM features associated with PAH, and to describe treatment modalities of these patients. Methods All cases of IIM-PAH were retrieved from the French PH Registry, which gathers PAH patients prospectively enrolled by 21 referral centers across France. Patients were excluded if they had an extensive ILD or overlap syndrome. Characteristics of IIM-PAH patients were compared to a control group of IIM patients without PH. Results Among the 5223 PAH patients in the Registry, 34 had a diagnosis of IIM. Among them, 3 IIM-PAH patients had no sign of extensive ILD or overlap syndrome, and were included in this study. In these patients, dermatomyositis (DM) was the only identified IIM. Two of them had a myopathic DM, confirmed by electromyography and biopsy. The last patient had an amyopathic DM, associated with anti-Ku antibodies. Pre-capillary PH was hemodynamically proven in all patients. PAH always developed after IIM onset, was severe in all cases, and led to a marked functional impairment. By pooling our cases with 6 previously reported patients, and comparing them to a control cohort of 35 IIM patients without PH, we identify several IIM characteristics possibly associated with PAH occurrence, including DM subtype (78% vs. 46%, p =0.02), skin involvement ( p =0.04), anti-SSA antibodies ( p =0.05) and peripheral microangiopathy ( p =0.06). Overall, IIM-PAH patients were managed by corticosteroids and/or immunosuppressants, either alone or combined with PAH therapy. Patients that did not receive PAH therapy did not seem to respond to IIM treatment alone. Conclusions Our study reports for the first time the rare but possible association of PAH and IIM in a large prospective PH Registry. In that setting, PAH seems associated with DM, skin involvement, peripheral microangiopathy and anti-SSA positivity. The best therapeutic strategy for IIM-PAH remains to be defined. Disclosure of Interest None declared
- Published
- 2016
- Full Text
- View/download PDF
9. Multifocal bronchial stenosis and extensive lobar atelectasis as a rare radiologic feature of severe eosinophilic asthma.
- Author
-
Phillips-Houlbracq M, Debray MP, Guyard A, Khoury R, Dombret MC, Le Brun M, Deneuville L, Dupin C, and Taillé C
- Subjects
- Humans, Constriction, Pathologic, Asthma, Pulmonary Atelectasis diagnostic imaging, Pulmonary Eosinophilia
- Published
- 2023
- Full Text
- View/download PDF
10. Determinants of survival after lung transplantation in telomerase-related gene mutation carriers: A retrospective cohort.
- Author
-
Phillips-Houlbracq M, Mal H, Cottin V, Gauvain C, Beier F, Sicre de Fontbrune F, Sidali S, Mornex JF, Hirschi S, Roux A, Weisenburger G, Roussel A, Wémeau-Stervinou L, Le Pavec J, Pison C, Marchand Adam S, Froidure A, Lazor R, Naccache JM, Jouneau S, Nunes H, Reynaud-Gaubert M, Le Borgne A, Boutboul D, Ba I, Boileau C, Crestani B, Kannengiesser C, and Borie R
- Subjects
- Humans, Male, Middle Aged, Mutation, Retrospective Studies, Idiopathic Pulmonary Fibrosis genetics, Idiopathic Pulmonary Fibrosis surgery, Lung Transplantation adverse effects, Telomerase genetics
- Abstract
Carriers of germline telomerase-related gene (TRG) mutations can show poor prognosis, with an increase in common hematological complications after lung transplantation (LT) for pulmonary fibrosis. The aim of this study was to describe the outcomes after LT in recipients carrying a germline TRG mutation and to identify the predictors of survival. In a multicenter cohort of LT patients, we retrospectively reviewed those carrying pathogenic TRG variations (n = 38; TERT, n = 23, TERC, n = 9, RTEL1, n = 6) between 2009 and 2018. The median age at LT was 54 years (interquartile range [IQR] 46-59); 68% were male and 71% had idiopathic pulmonary fibrosis. During the diagnosis of pulmonary fibrosis, 28 (74%) had a hematological disease, including eight with myelodysplasia. After a median follow-up of 26 months (IQR 15-46), 38 patients received LT. The overall post-LT median survival was 3.75 years (IQR 1.8-NA). The risk of death after LT was increased for patients with myelodysplasia (HR 4.1 [95% CI 1.5-11.5]) or short telomere (HR 2.2 [1.0-5.0]) before LT. After LT, all patients had anemia, 66% had thrombocytopenia, and 39% had neutropenia. Chronic lung allograft dysfunction frequency was 29% at 4 years. The present findings support the use of LT in TRG mutation carriers without myelodysplasia. Hematological evaluation should be systematically performed before LT., (© 2021 The American Society of Transplantation and the American Society of Transplant Surgeons.)
- Published
- 2022
- Full Text
- View/download PDF
11. Pathophysiology of Escherichia coli pneumonia: Respective contribution of pathogenicity islands to virulence.
- Author
-
Phillips-Houlbracq M, Ricard JD, Foucrier A, Yoder-Himes D, Gaudry S, Bex J, Messika J, Margetis D, Chatel J, Dobrindt U, Denamur E, and Roux D
- Subjects
- Adhesins, Bacterial genetics, Animals, Cross Infection microbiology, Disease Models, Animal, Escherichia coli Proteins genetics, Humans, Intensive Care Units, Male, Pneumonia, Bacterial microbiology, Pneumonia, Ventilator-Associated microbiology, Rats, Rats, Wistar, Urinary Tract Infections microbiology, Urinary Tract Infections physiopathology, Virulence genetics, Escherichia coli genetics, Escherichia coli pathogenicity, Escherichia coli Infections physiopathology, Genomic Islands genetics, Pneumonia, Bacterial physiopathology, Pneumonia, Ventilator-Associated physiopathology
- Abstract
Ventilator-associated pneumonia (VAP) remains the most frequent life-threatening nosocomial infection. Enterobacteriaceae including Escherichia coli are increasingly involved. If a cumulative effect of pathogenicity islands (PAIs) has been shown for E. coli virulence in urinary tract or systemic infections, very little is known regarding pathophysiology of E. coli pneumonia. This study aimed to determine the role of each of the 7 PAIs present in pathogenic E. coli strain 536 in pneumonia pathophysiology. We used mutant strains to screen pathophysiological role of PAI in a rat pneumonia model. We also test individual gene mutants within PAI identified to be involved in pneumonia pathogenesis. Finally, we determined the prevalence of these genes of interest in E. coli isolates from feces and airways of ventilated patients. Only PAIs I and III were significantly associated with rat pneumonia pathogenicity. Only the antigen-43 (Ag43) gene in PAI III was significantly associated with bacterial pathogenicity. The prevalence of tested genes in fecal and airway isolates of ventilated patients did not differ between isolates. In contrast, genes encoding Ag43, the F17-fimbriae subunits, HmuR and SepA were more prevalent in VAP isolates with statistical significance for hmuR when compared to airway colonizing isolates. The E. coli PAIs involved in lung pathogenicity differed from those involved in urinary tract and bloodstream infections. Overall, extraintestinal E. coli virulence seems to rely on a combination of numerous virulence genes that have a cumulative effect depending on the infection site., (Copyright © 2018 Elsevier GmbH. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
12. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
- Author
-
McLeer-Florin A, Duruisseaux M, Pinsolle J, Dubourd S, Mondet J, Phillips Houlbracq M, Magnat N, Fauré J, Chatagnon A, de Fraipont F, Giaj Levra M, Toffart AC, Ferretti G, Hainaut P, Brambilla E, Moro-Sibilot D, and Lantuejoul S
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung enzymology, Female, Gene Amplification, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Lung Neoplasms drug therapy, Lung Neoplasms enzymology, Male, Middle Aged, RNA, Neoplasm genetics, Sequence Analysis, RNA methods, Young Adult, Anaplastic Lymphoma Kinase genetics, Carcinoma, Non-Small-Cell Lung genetics, Crizotinib pharmacology, Lung Neoplasms genetics, Oncogene Proteins, Fusion genetics
- Abstract
Objectives: The aim of the present study was firstly to assess in a clinical setting the yields of an amplicon-based parallel RNA sequencing (RNA-seq) assay for ALK fusion transcript variants detection in comparison with immunohistochemistry (IHC) and fluorescent in-situ hybridization (FISH) in a selected population of ALK-positive and ALK-negative non-small cell lung cancer (NSCLC) cases, and secondly to evaluate the impact of the ALK variant on crizotinib efficacy., Materials and Methods: The cohort used for the assessment of the RNA-seq assay comprised 53 samples initially diagnosed as being ALK-positive based on the results obtained by IHC and/or FISH, and 23 ALK-negative samples. A distinction was made between 'truly' IHC/FISH positive or 'truly' IHC/FISH negative samples, and those for which the IHC and/or FISH were equivocal (IHC) or borderline-positive (FISH)., Results: On the overall population, RNA-seq sensitivity (Se) and specificity (Spe) were of 80% and 100%, respectively when IHC and FISH were combined. For the 31 'truly positive' samples, Se and Spe of 100% were reached. An ALK status could be assigned by RNA-seq in 10/10 of the equivocal and/or borderline-positive IHC/FISH cases, 2/7 IHC/FISH discordant cases. When crizotinib efficacy was evaluated according to the type of ALK variant, better clinical outcomes were observed in crizotinib-treated patients with EML4-ALK v1/v2/others variants compared to v3a/b variants., Conclusion: RNA-seq detects ALK rearrangements with a high sensitivity and specificity using only 10 ng of RNA. It appears to be a promising rescue technique for non-clear-cut IHC/FISH cases and also offers a unique opportunity to identify ALK fusion variants and evaluate their predictive value for ALK inhibitors efficacy., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
13. Pulmonary arterial hypertension in idiopathic inflammatory myopathies: Data from the French pulmonary hypertension registry and review of the literature.
- Author
-
Sanges S, Yelnik CM, Sitbon O, Benveniste O, Mariampillai K, Phillips-Houlbracq M, Pison C, Deligny C, Inamo J, Cottin V, Mouthon L, Launay D, Lambert M, Hatron PY, Rottat L, Humbert M, and Hachulla E
- Subjects
- Adrenal Cortex Hormones therapeutic use, Adult, Aged, Female, France epidemiology, Humans, Hypertension, Pulmonary drug therapy, Hypertension, Pulmonary epidemiology, Immunosuppressive Agents therapeutic use, Incidence, Male, Middle Aged, Myositis drug therapy, Prospective Studies, Registries, Retrospective Studies, Hypertension, Pulmonary etiology, Myositis complications
- Abstract
Occurrence of pulmonary arterial hypertension (PAH) in idiopathic inflammatory myopathies (IIMs) without extensive interstitial lung disease (ILD) has rarely been described in the medical literature. This study aimed to report all cases with association of PAH and IIM in the French Pulmonary Hypertension (PH) Registry, to identify IIM features associated with the presence of PAH, and to describe treatment modalities of these patients.All cases of IIM-PAH were retrieved from the French PH Registry, which gathers PH patients prospectively enrolled by 27 referral hospital centers across France. Patients were excluded if they had an extensive ILD or overlap syndrome. Characteristics of IIM-PAH patients were compared with a control group of IIM patients without PH.Among the 5223 PH patients in the Registry, 34 had a diagnosis of IIM. Among them, 3 IIM-PAH patients (2 females and 1 male) had no evidence of extensive ILD or overlap syndrome, and were included in this study. In these 3 patients, dermatomyositis (DM) was the only identified IIM. One patient had autoantibodies classically associated with IIM (anti-Ku). PAH had always developed after IIM onset, was severe in all cases, and led to a marked functional impairment.By pooling our cases with 6 patients previously reported in the literature, and comparing them with a control cohort of 35 IIM patients without PH, we identify several IIM characteristics possibly associated with PAH occurrence, including DM subtype (78% vs 46%; P = 0.02), skin involvement (P = 0.04), anti-SSA antibodies (P = 0.05), and peripheral microangiopathy (P = 0.06).Overall, IIM-PAH patients were managed by corticosteroids and/or immunosuppressants, either alone or combined with PAH therapy. Patients did not seem to respond to IIM treatment alone.Our study reports for the first time the rare but possible association of PAH and IIM in a large prospective PH Registry. In that setting, PAH seems associated with DM, skin involvement, peripheral microangiopathy, and anti-SSA positivity. The best therapeutic strategy for IIM-PAH remains to be defined., Competing Interests: The authors have no conflict of interest to declare in relation to this work.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.